Difference between revisions of "Part:BBa K1781002"

(Add a)
(Add an improvement to this part)
Line 6: Line 6:
  
 
==Improvement and New Application for ZHER2==
 
==Improvement and New Application for ZHER2==
<b>Group:</b> iGEM2021_Greatbay_SCIE
+
<b>Group:</b> iGEM2021_Greatbay_SCIE <br>
 
<b>Author:</b> iGEM2021_Greatbay_SCIE
 
<b>Author:</b> iGEM2021_Greatbay_SCIE
  

Revision as of 05:12, 20 October 2021


ZHER2 - affibody with affinity to cytoplasmic domain of HER2

ZHER2 was one of the first affibodies created and it binds to the Human Epidermal Growth Factor 2 (HER2). They originate from mutations in the Immunoglobin G Binding Domain of Protein A from Staphylococcus aureus. Affibodies are engineered to bind to larger proteins or peptides where they imitate monoclonal antibodies. They are used in a multitude of therapies in biotechnology to bioimaging. ZHER2 can particular be used as a protein-protein interaction tool, as well as a way to verify antibody interactions as it binds to the cytoplasmic domain of HER2 at a different epitope than the antibodies.

Improvement and New Application for ZHER2

Group: iGEM2021_Greatbay_SCIE
Author: iGEM2021_Greatbay_SCIE


Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal NgoMIV site found at 4
    Illegal AgeI site found at 220
  • 1000
    COMPATIBLE WITH RFC[1000]